Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0361)
| Name |
JP4-039
|
||||
|---|---|---|---|---|---|
| Synonyms |
JP4-039; CHEMBL3326504
Click to Show/Hide
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C23H42N3O4
|
||||
| Canonical SMILES |
CC(C)CC(C=CCC(=O)NC1CC(N(C(C1)(C)C)[O])(C)C)NC(=O)OC(C)(C)C
|
||||
| InChI |
InChI=1S/C23H42N3O4/c1-16(2)13-17(25-20(28)30-21(3,4)5)11-10-12-19(27)24-18-14-22(6,7)26(29)23(8,9)15-18/h10-11,16-18H,12-15H2,1-9H3,(H,24,27)(H,25,28)/b11-10+/t17-/m1/s1
|
||||
| InChIKey |
AJHRJWQXDNEJAG-SXSDINLZSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Pancreatic cancer | ICD-11: 2C10 | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Cell Process | Cell ferroptosis | |||
| In Vitro Model | BJeLR (Human foreskin fibroblasts) | |||
| PANC-1 cells | Pancreatic ductal adenocarcinoma | Homo sapiens | CVCL_0480 | |
| Response regulation | This study reveals the protective effects of XJB-5-131 and JP4-039 in pancreatic ductal adenocarcinoma BJeLR cells against erastin-induced and RSL3-induced ferroptosis. | |||